February 17, 2009 09:15 ET

CDEX Files FY2008 10KSB; Continued Record Revenues

TUCSON, AZ--(Marketwire - February 17, 2009) - CDEX Inc. (OTCBB: CEXI) filed its FY08 10KSB on February 13; FY08 accomplishments included record revenues (65% above FY07), 74% gross margins (65% in FY07), international expansion of the ValiMed™ product line, more than doubling of the ValiMed hospital client base, introduction of a new product line (ID2 Meth Scanner™), and domestic and international sales of both ValiMed and the ID2 Meth Scanner.

"FY08 was a year of positioning and great accomplishments for CDEX," said Malcolm Philips, CDEX CEO. "Even while we expanded significantly our existing ValiMed product line, introduced the new ID2 product line, and positioned ourselves for the future by increased R&D spending, we still reduced our net operating loss by over 18%. While the global economic downturn presents major challenges for every company, including CDEX, we are moving in the right direction and fully expect to be cash flow positive by the last quarter of 2009 -- our next major goal." (See expanded comments regarding FY08 in the Management Briefing Section of the CDEX Web Site at

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics. The ID2™ product line detects trace amounts or illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must raise additional funds as stated periodically in its SEC filings. For more information, visit

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks and uncertainties that cannot be accurately predicted or quantified and, consequently, actual results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information